TRAIL, Volume 67

1st Edition

Editor-in-Chiefs: Gerald Litwack
Hardcover ISBN: 9780127098678
eBook ISBN: 9780080522876
Imprint: Academic Press
Published Date: 7th May 2004
Page Count: 448
Tax/VAT will be calculated at check-out
225.00
135.00
170.00
198.00
Unavailable
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


Description

The discovery of TRAIL (TNF Related Apoptosis Inducing Ligand), also referred to as Apo-2, is in an era of intense research because TRAIL induces many cancer cells to undergo programmed cell death (apoptosis), while having no effect on normal cells. This important protein deserves extensive review at a formative time in the devlopement of our knowledge concerning its mechanism of action and the ways in which it can be used as a cancer chemotherapeutic agent. Consequently, this voume reviews the current status of research on TRAIL.

Key Features

Selected Contents:

  • Crystal Structure of RANK Ligand involved in bone metabolism
  • Promoter of TRAIL-R2 Gene
  • Monoclonal Antibodies against TRAIL
  • Modulation of TRAIL signaling complex
  • TRAIL in the airways
  • FLIP Protein and TRAIL-Induced Apoptosis
  • TRAIL and Ceramide
  • TRAIL and Viral Infection
  • TRAIL and Malignant Glioma

Readership

Molecular biologists, cellular biologists, & biochemists


Details

No. of pages:
448
Language:
English
Copyright:
© Academic Press 2004
Published:
Imprint:
Academic Press
eBook ISBN:
9780080522876
Hardcover ISBN:
9780127098678

About the Editor-in-Chiefs

Gerald Litwack Editor-in-Chief

Following a liberal arts education with a major in chemistry and biology at Hobart College, Gerald (Gerry) Litwack earned M.S. and PhD degrees in biochemistry from the University of Wisconsin, Madison where he served as a Lecturer in Enzymology before starting a postdoctoral fellowship from the National Foundation for Infantile Paralysis at the Biochemical Institute of the Sorbonne in Paris. His first academic position was assistant professor of biochemistry at Rutgers University where he started his work on hormone action for six years. During this period, he did a sabbatical at the University of California, Berkeley, where he concentrated on rapid enzyme kinetics. In 1960 he accepted an offer of an associate professorship at the University of Pennsylvania Graduate School of Medicine. In 1964, he was invited to be full professor of biochemistry at The Fels Institute for Cancer Research and Molecular Biology at Temple Medical School, simultaneously with a Career Development Award from the NIH, where he later was named Deputy Director of the Institute and the Laura H. Carnell Professor in biochemistry. Subsequently, he was given the Faculty Research Award. He co-discovered ligandin, later found to be in the family of glutathione S-transferases, enzymes that protect the body from carcinogens. In 1991, he moved to the Jefferson Medical College at Thomas Jefferson University as Professor of Biochemistry, Chair of the Department of Pharmacology and Deputy Director of the Kimmel Cancer Research Institute. Later, he became chair of the combined Department of Biochemistry and Molecular Pharmacology and concurrently held the position of Vice Dean for Research. In 2003, he moved to Los Angeles and from 2004-2006 was a Visiting Scholar at the University of California, Los Angeles, in the Department of Biological Chemistry of the Geffen School of Medicine and, in this period, wrote “Human Biochemistry and Disease” a volume of 1254 pages. In 2007, he moved to Scranton,

Affiliations and Expertise

Toluca Lake, North Hollywood, California, USA